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PERSPECTIVE OPEN
Systems medicine disease maps: community-driven
comprehensive representation of disease mechanisms
Alexander Mazein 1, Marek Ostaszewski2, Inna Kuperstein 3,4,5,6, Steven Watterson7, Nicolas Le Novère8, Diane Lefaudeux1,
Bertrand De Meulder1, Johann Pellet1, Irina Balaur 1, Mansoor Saqi1, Maria Manuela Nogueira1, Feng He 9, Andrew Parton 7,
Nathanaël Lemonnier10, Piotr Gawron2, Stephan Gebel2, Pierre Hainaut10, Markus Ollert9,11, Ugur Dogrusoz12,
Emmanuel Barillot 3,4,5,6, Andrei Zinovyev 3,4,5,6, Reinhard Schneider2, Rudi Balling2 and Charles Auffray 1
The development of computational approaches in systems biology has reached a state of maturity that allows their transition to
systems medicine. Despite this progress, intuitive visualisation and context-dependent knowledge representation still present a
major bottleneck. In this paper, we describe the Disease Maps Project, an effort towards a community-driven computationally
readable comprehensive representation of disease mechanisms. We outline the key principles and the framework required for the
success of this initiative, including use of best practices, standards and protocols. We apply a modular approach to ensure efﬁcient
sharing and reuse of resources for projects dedicated to speciﬁc diseases. Community-wide use of disease maps will accelerate the
conduct of biomedical research and lead to new disease ontologies deﬁned from mechanism-based disease endotypes rather than
phenotypes.
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THE CONCEPT
Disease mechanisms in the context of translational medicine
projects
Large amounts of high-throughput data are routinely generated in
an effort to better understand diseases, adding to our extensive
and diverse biomedical knowledge. Common objectives include
the identiﬁcation of disease biomarkers, molecular mechanisms,
potential drug targets and disease subtypes for better diagnostics
and stratiﬁcation of patients.1
Using such diverse and complex high-throughput datasets to
meet the current and future demands of research in basic and
translational medicine is challenging. Our experience in large-scale
translational medicine projects (Supplementary material S1) is that
the difﬁculties associated with such tasks are often vastly
underestimated. When it comes to disease-speciﬁc functional
analysis and systematic data interpretation, computational and
mathematical tools have not developed at the same pace as
laboratory technologies. Interpreting data in a given context still
mainly relies on statistical approaches, e.g., pathway enrichment
analysis. To advance beyond context-independent use of canoni-
cal pathways, dedicated knowledge maps are needed, which
would provide the molecular mechanisms involved in given
diseases.
Charting maps, from geography to anatomy, is an essential
scientiﬁc activity in many ﬁelds. Maps do not only chart a territory
but also facilitate our understanding.2 A mechanistic representa-
tion was ﬁrst applied on a large scale to metabolic pathways in the
form of the wall charts created by Nicholson3 and Michal.4
Mechanistic representation of extensive signalling pathways was
pioneered by Kurt Kohn5 and Hiroaki Kitano6 and developed into
the Systems Biology Graphical Notation (SBGN) standard.7
In order to bridge knowledge maps and the big data of health-
care research, we have engaged in the development of highly
detailed and speciﬁc representations of known disease mechan-
isms (Table 1).8–10 Having these resources, we employed
complementary techniques that use prior knowledge for data
and network analysis and hypothesis generation11 in systems
medicine projects (Fig. 1).
This paper describes the concept of a disease map, a resource
that focusses on disease mechanisms and can be used to develop
computational models of disease with advanced data interpreta-
tion methods. We put forward the view that disease maps should
be developed through a community effort that facilitates
collaborative research in support of translational medicine
projects.
Disease map deﬁnition
A disease map can be deﬁned as a comprehensive, knowledge-
based representation of disease mechanisms. Essentially, it is a
conceptual model of a disease. It contains disease-related
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signalling, metabolic and gene regulatory processes with evidence
of their relationships to pathophysiological causes and out-
comes8–10 (Fig. 2). To describe the complexity of a disease it is
important to capture not only biochemical interactions but also
physiological mechanisms.
A disease map is represented graphically and is encoded in a
standard computer-readable and human-readable format, allow-
ing its transformation, partially or wholly, into mathematical
models for predictive analysis. We speciﬁcally distinguish the
literature-derived conceptual model of a disease and the different
types of mathematical models that can be produced from it. This
way we make the core resource updatable and sustainable while
enabling the production of various models by adding
assumptions, hypothetical mechanisms and model parameters.
The proposed new mechanisms are then conﬁrmed or rejected,
and the conceptual core model updated accordingly.
Development of disease maps relies on an active involvement
of domain experts. In contrast to most knowledge management
solutions that directly reuse available information stored in various
databases, building disease maps requires to actively look for
mechanistic details and add missing pieces.
The resulting representations provide curated systems-level
views of the mechanisms associated with a given disease for
interpretation by biomedical experts as well as a broader
audience, e.g., physicians, teachers and students.
Table 1. Comparison of published disease maps
Feature AlzPathway Parkinson’s disease map ACSN
Webpage http://alzpathway.org http://pdmap.uni.lu https://acsn.curie.fr
Online exploration Payao (Apache Flex) MINERVA (Google Maps API) NaviCell (Google Maps API)
Content development CellDesignera CellDesignera CellDesignera
Standard formats SBML, BioPAX SBML SBML, BioPAX
Number of nodes 1538 5073 5975
Number of processes 1127 2108 4826
Number of proteins 721 2973 2371
Number of metabolites 300 703 595
Number of genes 33 202 159
Number of references >100 Review articles 1307 2919
Disease maps represent hallmark pathways and processes associated with the disease: Alzheimer’s disease,8,54 Parkinson’s disease9 and cancer.10,55 The three
disease maps are the result of manual curation of the relevant literature and provide a manually drawn layout using CellDesigner (http://www.celldesigner.
org). The exploration of the maps is available through Payao,56 MINERVA27 and NaviCell.28,29
aCellDesigner supports graphical notation and symbols based on the Systems Biology Graphical Notation7 Process Description language Level 1 draft as of
May 2008 (http://www.celldesigner.org/features.html). To visualise diagrams in the current version of the SBGN standard (http://sbgn.org) it is possible to use
the CellDesigner SBGN Viewer (http://www.celldesigner.org/help/)
Fig. 1 Outline of the systems medicine rationale. The diagram represents the transformation of diverse prior knowledge and newly generated
data into hypotheses using computational and mathematical methods, tools and approaches appropriate for each step
Systems medicine disease maps: community-driven
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Multiscale knowledge management is at the heart of the
disease map concept. This means developing and exploiting
protocols for the high-quality representation of information at
different levels of granularity including subcellular, cellular, tissue,
organ and organism levels. Although we have become better at
describing biological events, there are still challenges to be faced,
such as the representation of the physiological layers and the
inclusion of regulatory mechanisms. Describing diseases in
standardised formats will simplify cross-disease comparisons and
will facilitate the identiﬁcation of similarities and differences in
molecular and cellular modules between diseases.
The challenges in assembling disease maps and suggested
solutions
Determining the content. Taking into account the high level of
connectivity in biological networks, potentially many biological
processes can be linked to or affected by a disease. One of the ﬁrst
steps in a disease map construction is therefore setting the scope:
deﬁning hallmark molecular mechanisms and affected tissues and
drafting their relationships. From this step onwards the curators of
a disease map should consult domain experts. Community-driven
expert-approved construction is the best strategy to build a
trusted resource. The developed conceptual model of a disease
Fig. 2 A fragment of the Parkinson’s disease map. a A disease map repository allows visual multiscale exploration of the contextualised,
disease-relevant mechanisms. Here, the contents of the Parkinson’s Disease map can be explored across scales from the neuronal
environment to the detailed molecular pathobiology of the disease. Higher scales emerge from the underlying mechanistic descriptions. b
Mechanistic details of dopamine metabolism in the dopaminergic neurones are shown. The involvement of Parkinson’s disease familial genes,
PARK2 (Parkin), PARK7 (DJ-1) and SNCA (alpha-synuclein) is highlighted. Excessive oxidation of dopamine into dopamine quinone may lead to
conformational changes in proteins and subsequently result in molecular neuropathology associated with Parkinson’s, marked as “disease
endpoints” in the ﬁgure
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can be further reﬁned in the cycle of producing and then
conﬁrming or rejecting hypotheses.
Involving domain experts. The major challenge of offering a
consensus view is creating a community of leading domain
experts to participate actively in the development of each disease
map. The experience of the already published maps ensures that
this can be done successfully. For example, the Atlas of Cancer
Signalling Networks (ACSN) and the Parkinson’s Disease Map
continuously work with dozens of experts and organise regular
dedicated workshops (https://wwwen.uni.lu/lcsb/research/
parkinson_s_disease_map/expert_curation, https://acsn.curie.fr/
about.html). Domain experts are joining because they are
motivated not only by their own research interest, but also by
the possibility of storing and sharing their experience and
concepts across multiple diseases that may have common
underlying molecular bases, and by the beneﬁts a description of
disease mechanisms can bring to the scientiﬁc community and
patients. In many cases clinicians themselves initiate the devel-
opment of such resources. This high-quality approach is
assimilated by every project that joins the effort. Best practices
are being further reﬁned and currently the process assumes
working on an overview diagram where the main hallmarks are
being deﬁned and also on clarifying speciﬁc focussed detailed
mechanisms important for disease progression.
Complexity management. With a growing body of literature, a
disease map is becoming increasingly extensive and complex.
Many of the published disease map resources8–10,12 ﬁrst worked
on smaller sub-maps before creating a large single map. We would
like to build on this experience of working with sub-maps and
explore the idea of hierarchically structured maps learning from
the approach used in Reactome.13 This way, instead of constantly
extending a single map, we can offer an interactive navigation
through the multilayer network using comparatively small easy-
readable, easy-updatable and often reusable sub-maps.
Manually designed diagrams. One of the major time-consuming
tasks is manually designing human-readable maps. The layout of
such maps reﬂects a biological concept in an easily-
comprehensible form. The currently available algorithms for
automatic layout are still insufﬁcient for competing with human-
made maps. Solving this problem would offer new opportunities
and noticeably improve the development and management of
large-scale biological networks.
THE DISEASE MAPS PROJECT
A community of communities
Disease map generation and curation require an extremely broad
and deep domain knowledge and is considerably resource
intensive. The development of such maps to an acceptable level
of rigour and interoperability, the assembly of the complementary
computational and mathematical tools require signiﬁcant physio-
logical and biomedical expertise combined with analytical skills.
Hence, an activity of this scale and scope can only be undertaken
as a synergistic effort of many communities dedicated to speciﬁc
diseases. The members of these communities need to agree on
working according to an approved set of standards for curation,
representation and accessibility and to develop complementary
tools that exploit the data captured with these standards.
The following themes are fundamental to this large-scale
collaborative network.
● 1. A disease expert group. A total of 5 to 20 domain experts
(clinicians, experimental biologists) contribute to each disease
map (Fig. 3a) and collaborate with the computational
biologists and curators who develop the map.
● 2. These disease expert groups are brought together in order to
enable sharing and exchange of expertise and best practices
(Fig. 3b). For example, different chronic diseases are likely to
have common inﬂammatory mechanisms and those groups
would beneﬁt from working together.
● 3. Another layer of the network includes pathway expert
groups, each focussed on particular biological processes or
pathway modules (Fig. 3c). We anticipate the emergence of a
new type of high-quality database in which reference path-
ways would be developed and systematically updated by the
Fig. 3 The Disease Maps Project as a community of communities. a A collaboration for building one disease map. b Disease expert groups. c
Pathway expert groups. Light colours: computational biology groups. Solid colours: domain experts. The Disease Maps hub is to be used for
sharing experience, improving best practices and agreed-upon protocols, exchanging reusable biological processes and pathway modules. It
is also an effort to create an infrastructure and set of tools to help each project to progress faster
Systems medicine disease maps: community-driven
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best experts in the respective ﬁelds, and in which the role of
pathways can be explored across diseases.
● 4. Support of a larger scientiﬁc community of interconnected
projects in order to advance the required technologies and
avoid duplicated activities.
In order to address these challenges proactively and in a
sustainable manner, the Luxembourg Centre for Systems Biome-
dicine, Institut Curie and the European Institute for Systems
Biology and Medicine have initiated the formation of a
collaborative network, the “Disease Maps Project” (http://disease-
maps.org), that takes an active role in the development of disease
maps by fostering knowledge exchange and integrating the
activities into a community effort. The ﬁrst face-to-face community
meeting (http://disease-maps.org/events) included groups from
six countries developing disease maps for anaphylaxis, asthma,
atherosclerosis, cystic ﬁbrosis, cancer, multiple sclerosis, Parkin-
son’s disease and rheumatoid arthritis (http://disease-maps.org/
projects). Other groups then joined, developing maps on, e.g.,
acute kidney injury and coronary artery disease. The second
community meeting was focussed on mathematical modelling,
integrating resources and coordinating activities with friendly
projects.14 Additional activities are in preparation and the list of
maps is continuously growing.
Expected development of the project
The Disease Maps Project builds on the research interests of many
groups in understanding the mechanisms of particular diseases.
This ensures its natural expansion and efﬁciency: saving time and
resources by sharing tasks and investing together in the
development of the required tools and pipelines. We anticipate
that many disease maps will be initiated and supported within the
next several years, which will transform into new technologies
tested and made available for rapid advances in translational
research.
One of the important driving forces that bring separate groups
together is the interest in studying disease comorbidities and
shared mechanisms. In addition, we put emphasis on initiating
clusters of disease maps for diseases that are shown to have
similar mechanisms: allergic diseases, autoimmune diseases,
neurodegenerative disorders and cancers of different origins
and types. For example, we aim to investigate common
mechanisms of asthma (ongoing effort, advanced stage), allergic
rhinitis (planning stage) and atopic dermatitis (planning stage).
Agreements on collaboration and developing technologies
(http://disease-maps.org/relatedefforts) are reached with comple-
mentary efforts such as WikiPathways15 (https://wikipathways.org),
Pathway Commons16 (http://www.pathwaycommons.org), the
Physiome Project17 (http://physiomeproject.org), Virtual Metabolic
Human18 (https://vmh.uni.lu) and the Garuda Alliance (http://
www.garuda-alliance.org). In each case, we identiﬁed overlapping
activities and directions of research. Speciﬁc common interests are
standard formats, interoperability among pathway resources,
reuse of pathway modules (WikiPathways, Pathway Commons),
description and modelling of physiological and pathophysiologi-
cal mechanisms (Physiome), linking metabolic and signalling
networks (Virtual Metabolic Human) and pipelines and commu-
nication between tools (Garuda). Starting from small focussed
collaborative projects, we plan to establish common frameworks
and aim to progress together as partners while optimising the use
of resources and the expertise.
Relationships between normal and disease pathways should be
further explored. Developing a disease map often means that (1)
pathway information is reused and contextualised for a speciﬁc
condition and cell type, or/and (2) the pathway structure is
modiﬁed by a disease. The structure of a pathway often remains
the same but the concentrations of the involved proteins and
metabolites change signiﬁcantly as the disease progresses; for
example, the FcεRI activation by IgE and allergen in asthma leads
to the production of eicosanoids.19 In other cases, for instance in
cystic ﬁbrosis, it is mainly about modiﬁed or interrupted pathways
when a mutation causes an altered life cycle of the CFTR protein.20
Leveraging non-disease pathway resources, ﬂexible navigation
within normal and altered-by-disease pathways, the ability to
compare the healthy and disease state would be important for the
future advances of the Disease Maps Project. There is a need for a
technology for comparing pathway modules, determining what
contributes to a well-developed reconstruction, on-the-ﬂy
decision-making for choosing an appropriate module for a
particular disease map.
The Disease Maps Project also aims to align its work with the
European-wide research infrastructures roadmap (http://www.
esfri.eu/roadmap-2016), e.g., as part of CORBEL (Coordinated
Research Infrastructures Building Enduring Life-science Services;
http://www.corbel-project.eu).
Integrating resources
Prior to the Disease Maps initiative, the published reconstruc-
tions8–10,12 used different ways to deliver their maps to users. To
review several projects, users would have to go to individual
project pages and, in most cases, use different systems employed
for map browsing. During our second community meeting we
started discussing the exploration of disease maps via web-
platforms and integration of maps in a shared repository.14
The ﬁrst step for integrating various disease maps is agreeing
on shared formats as the common ground for all the involved
projects. The maps should be available in the established
standards such as SBGN, systems biology markup language
(SBML)21 and BioPAX.22 Neo4j graph database is another frame-
work to apply as it is well suited for queries via its declarative
Cypher language. The graph database approach has been shown
to facilitate management and exploration of biomedical knowl-
edge.23 Neo4j format is used, for example, for Recon224 and
Reactome.25 With this prospect in mind, we have developed a tool
for converting SBGN-ML to Neo4j format.26
Reusable disease map modules can be stored in pathway-
oriented databases. A solution can be found in collaboration with
Pathway Commons,16 WikiPathways15 and Reactome25 while
minimising duplicated activities and addressing compatibility
issues. The disease maps themselves should be available for
browsing and exploration in a uniﬁed way via a centralised easily
accessible web repository using platforms such as MINERVA,27
NaviCell28,29 and iPathways+12 (http://www.ipathways.org/plus).
The pillars of the community effort
The key aspect of the Disease Maps Project is the interoperability
between various disease maps. An agreement on common
guidelines and standards will enable projects to help each other,
share common tasks and promote trust in the quality of content
provided by another group.
We propose to build this community effort upon the following
guiding principles.
Open access. We believe that this is an essential principle
supporting the interests of each of the individual groups as well
as industrial partners. Beneﬁts derive from applying the disease
maps to speciﬁc questions, not from the ownership of the
reference maps. Open access invites advanced domain expertise
on a larger scale and provides a better chance of developing a
trusted reference resource for a particular disease.
Standard formats. Efﬁcient knowledge exchange derives from
the use and development of standardised formats. Speciﬁc visual
formats for disease maps are the SBGN Process Description and
Activity Flow languages (Fig. 4).7,30 The maps should be made
Systems medicine disease maps: community-driven
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accessible in a variety of formats including SBML,21 BioPAX22 and
Neo4j.26 The recently published System Biology Format Con-
verter31 makes the task of communication between different
formats much simpler.
Modular approach. Process information in disease maps is
organised as reusable modules and sub-networks. Modularity
facilitates exchange of disease map content and distributed
curation between groups. Another advantage, often overlooked, is
the possibility of having alternative versions, for instance with
different emphasis or granularity. Using modules allows the
networks to be extended almost indeﬁnitely while keeping the
system manageable.
Consistent quality. Shared protocols and guidelines help improve
the quality of the representations, in particular via consistency.
Credibility and adequate knowledge representation is a major
challenge in representing molecular mechanisms of a disease.
Best practices. The community approach and efﬁcient commu-
nication play an important role: new technological advances
developed by one group become immediately accessible to all the
participants.
Required resources, infrastructure and tools
One of the primary requisites for the Disease Maps Project is a
collection of biological process and pathway modules that can be
reused across maps. The focus could be on, e.g., common
components of inﬂammation, immune responses and metabolism
due to their pervasive nature in health and disease.
The process of map creation becomes more distributed and
offers new challenges for tool developers.14 With the advances in
cloud environments and web technologies, it is expected to have
an easy access to drawing maps online, and the development of
the web-based Newt Editor (http://newteditor.org) is a promising
step in that direction. Also, it becomes critical to have
collaborative editing capabilities similar to Google Docs (https://
www.google.com/docs/about), version control similar to Git
(https://git-scm.com/about) and support for crowdsourcing as
successfully implemented by WikiPathways.15 Advanced layout
algorithms are essential for further progress in semi-automatic
map construction and on-demand visualisation of complex
systems.32,33 We encourage the development of new tools as
open-source software to allow many groups to simultaneously
contribute and extend existing functionalities.
To accommodate the requirements of the activities and tasks
within the community project, it is important to balance the use of
the well-established intensively used software and a step-by-step
exploration to the desired new functionalities. As all the published
disease maps8–10,12 are created in CellDesigner, any new tools
need to ensure compatibility with such existing format and
provide the necessary interoperability.
Of particular importance are the issues of browsing and
semantic zooming29 through each disease map. The word “map”
implies the possibility of navigation and a “geographic-like” view
of molecular interactions. Generation of new hypotheses requires
capabilities for high-dimensional data overlay and tools that help
transform and analyse interaction networks on-the-ﬂy. Extensive
representations that include thousands of entities require
improved approaches for complexity management, e.g., organised
maps and semantic zooming to efﬁciently manage the content
online via such tools as MINERVA27 and NaviCell.28,29
Disease maps should be integrated with gene- and protein-
interaction-based approaches34–41 allowing further exploration
beyond known disease mechanisms to suggest new disease-
associated genes, processes and functional modules, and propose
unknown mechanisms.
Target users
The maps are primarily designed for computational biologists to
be applied in the ﬁeld of biomedical research. We also believe that
the disease maps can be used to teach molecular biology of
diseases to students. Some promising efforts have been made in
this direction among the community members. For example, the
Parkinson’s disease map is used for teaching at the University of
Luxembourg. The visual components of the maps are especially
appealing for explaining the complexity of the modelled disease
mechanisms to non-bioinformaticians. Medical doctors are inten-
sively involved in the development of disease maps. It is the
experience of the community members that the maps facilitate a
productive communication with physicians on disease mechan-
isms in conjunction with interpretation of experimental data.
At the same time, in their current form, the available maps are
not as easily accessible as we would like them to be. The amount
of details can be overwhelming if only the comprehensive view is
used. As discussed above, we work on presenting disease
mechanisms at different layers of granularity, with semantic
zooming through the layers. Each layer is essentially a user
interface for particular groups of users. The design is to be shaped
by the target groups. The community is aware of the necessity to
maintain the dialogue with a broader audience to improve the
content and the tools.
ONGOING ADVANCES AND FUTURE PERSPECTIVES
Closely working with clinicians and in the context of translational
research projects, disease map groups aim to make these
resources practically useful and applicable to addressing diag-
nostic and treatment questions.
Fig. 4 Representation of biological networks. Note that in all the four cases (a−d) the same set of proteins is shown but the relationships are
represented differently. The disease maps employ the two sequential representations: process descriptions and activity ﬂows. These
representations correspond to the Process Description and Activity Flow languages of the SBGN standard (adapted from ref. 53)
Systems medicine disease maps: community-driven
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Examples of disease maps applications for aiding functional
interpretation
While the Disease Maps effort is comparatively new and we are
only beginning to learn the power of the approach on a larger
scale, there are several examples of the use of disease maps
validated by experiments and/or using patients’ data.
Synergistic effect of combined treatment in cancer. An integrative
analysis of omics data from triple-negative breast cancer (TNBC)
cell lines showed that at least 70 non-overlapping genes were
robustly correlated with sensitivity to DNA repair inhibitors Dbait
(DT01) and Olaparib. Further analysis in the context of the ACSN
maps demonstrated that different speciﬁc defects in DNA repair
machinery were associated to Dbait or Olaparib sensitivity.
Network-based molecular signatures highlighted different
mechanisms for cells sensitive/resistant to Dbait and Olaparib,
suggesting a rationale for the combination of these two drugs.
The synergistic therapeutic effect was conﬁrmed for the combined
treatment with Dbait and poly(ADP-ribose) polymerase (PARP)
inhibitors in TNBC while sparing healthy tissue42 (Fig. 5).
Finding metastasis inducers in colon cancer through network
analysis. To study the interplay between signalling pathways
regulating the epithelial-to-mesenchymal transition (EMT), the
corresponding module was manually created and integrated into
the ACSN. Next, the network complexity reduction was performed
in BiNoM43 while preserving the core regulators of EMT. The
reduced network was used for modelling EMT phenotypes
resulting in the prediction that the simultaneous activation of
Notch and the loss of p53 can promote EMT.44 To validate this
hypothesis, a transgenic mouse model was created with a
constitutively active Notch1 receptor in a p53-deleted back-
ground. EMT markers were shown to be associated with
modulation of Notch and p53 gene expression in a manner
similar to the mice model supporting the predicted synergy
between these genes45 (Fig. 6).
It is important to note that the hypothesis driven from the
disease map was not intuitive and actually contradicted the
commonly accepted dogma in the colon cancer ﬁeld. This clearly
demonstrates that gathering cell signalling mechanisms together
may lead to discovering unexpected relationships and new
mechanisms.
Another example is available in Supplementary material S2:
complex intervention gene sets are derived from data-driven
network analysis for cancer patients in order to block “prolifera-
tion”’ phenotype, all the proliferation-inducing pathways have to
be identiﬁed and assembled together, including alternative
ones.46
Future perspectives for hypothesis generation and opening new
lines of investigation
Several directions are important for exploring further and carefully
collecting and improving successful pipelines.
Visualisation of complex data in the context of networks. The
ACSN has been used for deﬁning precise case–control groups of
patients, leading to their better stratiﬁcation in cancer.10 Similarly,
the Parkinson’s disease map has been used to interpret
Fig. 5 Sensitivity of TNBC cell lines to combination of DNA repair inhibitors. a Correlation analysis of survival to DT01 and Olaparib in TNBC
and control cell lines. b Molecular portraits of DT01 and Olaparib-sensitive/resistant TNBC cell lines visualised on DNA repair map. c Cell
survival to combination of DT01 and Olaparib. With DT01 (black line), without DT01 (grey line), dashed lines indicate calculated cell survival for
additive effect of two drugs (adapted from Jdey et al.42)
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differentially regulated brain transcripts based on a clinical
characterisation of patients.46 This stratiﬁed visualisation can be
reinforced by enrichment analysis tools.47,48 A generic methodol-
ogy would allow us to determine the biological process and
pathway patterns that correspond to distinct phenotypic patient
subgroups in a manner that facilitates patient stratiﬁcation.
Network analysis of disease-related mechanisms. Integrating high-
throughput patient data with information about the underlying
machinery has the potential to reveal molecular patterns speciﬁc
to disease subtypes and inform combinatorial diagnostics or
therapeutics.49 This enables the identiﬁcation of a set of
interactions, whose joint alteration can shift the state of the
network from unfavourable toward the desired outcome. For
instance, analysing disease map’s perturbations can help predict-
ing sensitivity to drugs based on network topology and choosing
a patient-speciﬁc combination of drug targets.50 Identiﬁcation of
condition-speciﬁc mechanisms can facilitate the identiﬁcation of
disease-speciﬁc and subtype-speciﬁc biomarkers, intervention
points or candidates for drug repurposing. A comparative analysis
allows understanding the relative importance of certain mechan-
isms, as in the case of the comparison of Parkinson’s disease and
ageing-related networks.51
Mathematical modelling: from static to dynamic representations. A
disease map is initially a static representation of current
knowledge, a collection of integrated scenarios, each reﬂecting a
certain stage of a disease or a disease subtype. To gain further
insights into the dynamic aspects of pathobiology and disease
progression, a disease map has to be transformed into a dynamic
mathematical model. The type of applicable mathematical model
depends on the quality and the level of detail of the knowledge
represented in a given disease map. Transcriptional regulatory and
signalling networks are well suited for logic models, e.g.,
deterministic and stochastic Boolean networks, or for rule-based
approaches. Metabolic networks can lead to steady-state
approaches such as ﬂux balance analysis.52 When detailed kinetic
data are available, quantitative chemical kinetic models can be
developed.53
EXPECTED IMPACT OF THE DISEASE MAPS PROJECT
The following elements outline the forthcoming development and
anticipated outcomes of the community effort.
● Establishing dedicated trusted reference resources on disease
mechanisms for many diseases. One disease or disease
subtype—one resource. Enabling advanced data interpreta-
tion, hypothesis generation, hypothesis prioritisation.
● Each disease map is a reﬂection of the current conceptual
model of what disease mechanisms are. Enabling various
types of mathematical modelling and predictions.
f
Fig. 6 Prediction of synthetic interaction combination to achieve invasive phenotype in colon cancer mice model. a Comprehensive signalling
network of EMT regulation, a part of the ACSN. b Scheme representing major players regulating EMT after structural analysis and reduction of
signalling network complexity. c Simplistic model of EMT regulation. d Simplistic model explaining regulation involving Notch, p53 and Wnt
pathways. e Lineage tracing of cell in tumour and in distant organs and immunostaining for major EMT markers. f Regulation of p53, Notch
and Wnt pathways in invasive colon cancer in human (TCGA data) (adapted from Chanrion et al.45)
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● Cross-disease comparison: speciﬁc and common disease
mechanism and corresponding biomarkers for better diag-
nostics. New possibilities for studying disease comorbidity.
● Enabling advanced systems pharmacology and suggesting
drug repositioning.
● Redeﬁning diseases and their subtypes based on molecular
signatures (endotypes). Preconditioning the development of
new-generation disease ontologies.
● Developing technologies and advancing research strategies in
computational biology and related ﬁelds through promoting a
modular approach, consolidating resources and avoiding
duplicated activities, in particular for building and managing
complex mathematical models and designing prototypes for
clinical decision support systems.
CONCLUSION
Our increasing knowledge of pathway networks and how they
vary across diseases has created a challenge of scale that needs
signiﬁcant collaborative activity to address. The Disease Maps
Project sets out to stimulate the development of the tools and
infrastructure that will support the current and next generation of
work in translational research. Covering a growing number of
diseases means that more and more proteins, RNAs, genes and
metabolites will be included into high-conﬁdence expert-veriﬁed
functional modules. In turn, this will lead to a better under-
standing of not only various diseases but also health and well-
being.
We are convinced that, through the establishment of a
multidisciplinary community with shared practices and standards,
the Disease Maps Project will facilitate powerful advances in the
discovery of disease mechanisms, cross-disease comparison,
ﬁnding disease comorbidities, suggesting drug repositioning
through the identiﬁcation of the common pathways. After careful
validation, disease ontologies can be redeﬁned based on disease
endotypes—conﬁrmed molecular mechanisms—thus paving the
way to more precise, cost-effective personalised medicine and
health-care solutions.
Data availability
All relevant data are available within the paper, Supplementary
Information and the Disease Maps website at http://disease-maps.
org/.
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